# Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma

> **NCT06505551** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **SCG Cell Therapy Pte. Ltd.** · enrollment: 66 (estimated)

## Conditions studied

- HPV-Related Squamous Cell Carcinoma
- HPV-Related Cervical Squamous Cell Carcinoma
- HPV-Related Vulvar Squamous Cell Carcinoma
- HPV-Related Penile Squamous Cell Carcinoma
- HPV-Related Vaginal Squamous Cell Carcinoma
- HPV-Related Anal Squamous Cell Carcinoma
- HPV-Related Head and Neck Cancer

## Interventions

- **BIOLOGICAL:** SCG142
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT06505551
- **Lead sponsor:** SCG Cell Therapy Pte. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10
- **Primary completion:** 2026-12
- **Final completion:** 2028-12
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2024-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06505551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06505551, "Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06505551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*